Mechanistic underpinning of CV benefit observed with icosapent ethyl

Media formats available:

Use of ARNI in HFpEF patients reduces NT-proBNP levels
Use of ARNI in HFpEF patients reduces NT-proBNP levels
ACC 2020
Use of ARNI in HFpEF patients reduces NT-proBNP levels
- Jonathan Cunningham, MD
Stopping with aspirin after 3 months DAPT is safe in a wide range of patients
Stopping with aspirin after 3 months DAPT is safe in a wide range of patients
ACC 2020
Stopping with aspirin after 3 months DAPT is safe in a wide range of patients
- Prof. Freek Verheugt, MD
Higher rate of smoking cessation with e-cigarettes compared to counseling
Higher rate of smoking cessation with e-cigarettes compared to counseling
ACC 2020
Higher rate of smoking cessation with e-cigarettes compared to counseling
- Prof. Mark Eisenberg, MD
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
ACC 2020
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
- Prof. Frederick Raal

PACE-CME